Ketorolac Eg (Ketorolac Trometamol)

Ketorolac trometamol blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, preventing the formation of prostaglandins that sensitize nerve endings and promote inflammation. This inhibition reduces pain signaling and swelling, providing effective analgesia without acting on opioid pathways.

The specific dose and duration of Ketorolac Eg are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and overall risk profile. Healthcare professionals follow local guidelines and product labeling to set an appropriate regimen.

Ketorolac is generally avoided in the third trimester of pregnancy because it may affect fetal circulation. Use during earlier stages or while breastfeeding should only occur if the prescriber judges that the potential benefits outweigh the possible risks to the mother or infant.

To request Ketorolac Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and any necessary import documentation.

Compared with other NSAIDs, ketorolac provides a higher potency of analgesia, often comparable to weak opioids, but it carries a greater risk of renal and gastrointestinal adverse effects. Unlike opioids, it does not cause respiratory depression, but its use is limited to short‑term therapy to minimise toxicity.

Ketorolac Eg should be stored below 25 °C in its original packaging, protected from light and moisture. The product must be kept in a controlled environment to maintain sterility and potency, and any unused portion should be discarded according to local regulations after the recommended beyond‑use date.

Ketorolac Eg is supplied as a sterile injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are selected by the healthcare professional, who follows standard aseptic techniques and monitors the patient for any immediate adverse reactions.

The most serious risks include gastrointestinal bleeding or perforation, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke, particularly when used in high‑risk patients or for longer than recommended.

Ketorolac Eg is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, those with active peptic ulcer disease, severe renal impairment, recent coronary artery bypass graft surgery, and in the third trimester of pregnancy. It should also be avoided in patients receiving other NSAIDs or aspirin without medical supervision.